The use of biologics before and during pregnancy is not associated with an increased risk of preterm delivery or small-for-gestational-age births, a study in Annals of the Rheumatic Diseases finds.
Here are three things to know.
1. The population-based study included women in British Columbia, Canada, with one or more autoimmune diseases who had pregnancies between Jan. 1, 2002, and Dec. 31, 2012.
2. The study authors defined exposure to biologics as having at least one biologic prescription three months before or during pregnancy.
3. There was no statistically significant difference in preterm delivery or small-for-gestational-age births between babies exposed to biologics and non-exposed babies.
More articles on biologics:
MedImmune to create standalone biologics company Viela Bio: 5 things to know
Biologics, opioids will be magic words at AAOS 2018 meeting: 5 insights